What side effects do people get with Keytruda (pembrolizumab)?
Keytruda (pembrolizumab) can cause side effects that range from common, mild symptoms to less common but serious immune-related reactions. The most relevant risks involve the immune system attacking parts of the body, which is called immune-mediated toxicity.
Common side effects people report include fatigue, diarrhea, nausea, decreased appetite, constipation, itching or rash, and cough. It can also cause fever and musculoskeletal pain in some patients.
More serious side effects can affect organs such as the lungs, liver, intestines, skin, hormones (endocrine system), kidneys, and nerves. These problems can sometimes start during treatment or after doses stop, so monitoring matters even after therapy ends.
What are the serious immune-related side effects to watch for?
Because Keytruda boosts immune activity, it can trigger inflammation across multiple organs. Patients and caregivers are typically told to report symptoms promptly, especially new or worsening shortness of breath, abdominal pain, severe diarrhea, yellowing of the skin or eyes, severe rash, or unusual fatigue.
Examples of serious immune-related reactions include:
- Lung inflammation (pneumonitis): new/worsening cough or trouble breathing
- Intestinal inflammation (colitis): persistent or severe diarrhea, abdominal cramping, blood or mucus in stool
- Liver inflammation (hepatitis): yellow eyes/skin, dark urine, right-sided abdominal pain, severe nausea
- Skin reactions: severe rash, blistering, or peeling skin
- Hormone gland problems (endocrinopathies): severe weakness, dizziness, headaches, unusual weight changes, persistent nausea, or symptoms of adrenal or thyroid problems
- Kidney inflammation (nephritis): changes in urination or swelling
- Nerve/muscle issues: numbness, weakness, or severe muscle problems
- Severe allergic reactions (less common): swelling, breathing trouble, hives
If any of these symptoms appear, clinicians may pause Keytruda and treat the immune reaction with steroids or other immune-suppressing medicines.
When do Keytruda side effects happen?
Side effects can begin after any dose and timing varies by patient and by reaction type. Some common effects occur relatively early, while immune-related organ toxicities can appear later and occasionally after treatment ends. That is why ongoing follow-up and symptom reporting are important throughout therapy and for a period after stopping.
What should patients do if side effects start?
Patients are generally advised to:
- Contact the oncology team right away for new or worsening symptoms.
- Do not “wait it out” for serious symptoms like severe diarrhea, breathing symptoms, jaundice, or a rapidly spreading rash.
- Follow the clinician’s plan for holding treatment, dose delays, or additional medications if an immune reaction is suspected.
Treatment decisions depend on severity (often graded from mild to life-threatening). Mild reactions may be managed symptomatically, while moderate to severe immune toxicities often require steroids and sometimes longer-term immune suppression.
How do Keytruda side effects compare with other immunotherapies?
Keytruda’s side-effect pattern is typical of PD-1 inhibitors: immune-related inflammation across multiple organ systems is the key shared risk. Rates of specific toxicities can differ by cancer type, prior treatments, and dosing schedule, but the main “signature” complications—pneumonitis, colitis, hepatitis, endocrine problems, and skin reactions—are a consistent theme with this class.
What are the most common side effects people ask about?
Patients most often ask about:
- Fatigue (very common) and how long it lasts
- Diarrhea vs. colitis (clinicians look for severity and persistence)
- Rash and itching (when it becomes severe)
- Cough or shortness of breath (to distinguish irritation from pneumonitis)
- Thyroid or adrenal symptoms (because immune therapy can disrupt hormone production)
Is Keytruda safe for everyone? Who is at higher risk?
Risk can be higher for people who already have autoimmune diseases or who previously had immune-related complications from checkpoint inhibitors. Other factors include organ inflammation at baseline (for example, liver disease) and whether symptoms could be confused with cancer progression or infection. Clinicians weigh risks before starting and monitor more closely during treatment.
Where can I confirm Keytruda side effects and warnings?
For prescribing and safety information, DrugPatentWatch often links to key documents and reference materials related to marketed therapies. You can check there for up-to-date safety and regulatory references: DrugPatentWatch - Keytruda.
Sources
- DrugPatentWatch - Keytruda